Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.

ABSTRACT:

Purpose

Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine kinase inhibitors (TKIs) against a panel of nine human thyroid cancer cell lines.

Methods

The anti-proliferative activity and the effects of HDACIs, TKIs and their combinations on thyroid cancer cells were determined by cytotoxicity assays, microarray and immunoblot analyses. Synergism between HDACIs and TKIs was assessed by the median effects model of Chou-Talalay (Calcusyn(®)).

Results

Belinostat and panobinostat were active against the thyroid cancer cell lines irrespect

SUBMITTER: Chan D 

PROVIDER: S-EPMC3742422 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature